Windtree Q1 net loss $4.1M; runway extended via $10.8M offering; EU patent granted

WINDTREE THERAPEUTICS INC /DE/

Net loss $4.1M ($4.76/sh) vs $8.1M in Q1 2022; operating loss narrowed to $4.2M from $8.3M.
Cash $4.2M as of Mar 31; April public offering raised $10.8M net, funding through Q1 2024.
R&D expense fell 74% to $1.4M; G&A down 23% to $2.3M; average monthly cash burn cut 58% YoY.
European Patent Office granted SERCA2a activator patent coverage through July 2038.
Regained Nasdaq minimum bid price compliance; publication on istaroxime cardiogenic shock dose-response.

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

WINDTREE THERAPEUTICS INC /DE/ reported quarter ended March 31, 2023 results: net income net loss of $4.1 million, EPS $4.76 per basic share.

Period: quarter ended March 31, 2023
Net income: net loss of $4.1 million
EPS: $4.76 per basic share
Result: reported results

Exact text from the filing

The Company reported a net loss of $4.1 million ( $4.76 per basic share) on 0.9 million weighted-average common shares outstanding for the quarter ended March 31, 2023 , compared to a net loss of $8.1 million ( $14.36 per basic share) on 0.6 million weighted average common shares outstanding for the comparable period in 2022 .

View on SEC.gov

8 earnings releases filed in the last 30 days. Browse all earnings releases →

WINDTREE THERAPEUTICS INC /DE/ filing history →

Source: SEC EDGAR

accession 0001437749-23-014595

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.